B
PDLI

Baird’s PDL BioPharma, Inc. PDLI Stock Holding History

Baird’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$469K Sell
66,712
-748
-1% -$5.42K ﹤0.01% 975
2014
Q4 		$520K Buy
67,460
+5,945
+10% +$47K 0.01% 935
2014
Q3 		$460K Sell
61,515
-113
-0.2% -$1.05K 0.01% 863
2014
Q2 		$597K Buy
61,628
+2,850
+5% +$25.4K 0.01% 796
2014
Q1 		$488K Buy
58,778
+828
+1% +$7.1K 0.01% 865
2013
Q4 		$489K Buy
+57,950
New +$488K 0.01% 844

Other funds holding PDLI

First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

Baird's PDLI Position: Q1 2015 in Review

Baird reduced its PDL BioPharma, Inc. (PDLI) stake by 1.1% in Q1 2015, selling an estimated $5.42K and leaving 66,712 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #975.

Baird first reported a position in PDLI in Q4 2013 and has held it in 6 quarters since. The position peaked at $597K in Q2 2014. 215 funds tracked by Wall St. Rank hold PDLI as of Q1 2015.

  • Baird held 66,712 shares of PDL BioPharma, Inc. worth $469K as of Q1 2015.
  • Baird sold 748 PDL BioPharma, Inc. shares in Q1 2015, an estimated $5.42K.
  • PDL BioPharma, Inc. made up ﹤0.01% of Baird's portfolio in Q1 2015, its #975 holding.
  • Baird first reported a position in PDL BioPharma, Inc. in Q4 2013 and has held it in 6 quarters since.
  • Baird's PDL BioPharma, Inc. position peaked at $597K in Q2 2014.
  • 215 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.